SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility following a failed orbital insertion of its BlueBird-7 satellite, which was launched by Blue Origin. The community is heavily divided between panic-selling due to potential launch delays and long-term investors viewing the dip as a prime buying opportunity, focusing on the company's insurance coverage and upcoming launch schedule.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining intense investor attention as participants speculate on imminent data readouts from the REGAL Phase 3 trial and upcoming AACR conference presentations for SLS009. The community is deeply divided, with bulls pointing to extended survival signals and institutional positioning as catalysts for a potential squeeze, while bears highlight concerns over trial design and the company's long-term financial viability.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is capturing significant community attention as it aligns its brand with 420 culture, driven by a series of ongoing digital events and a push toward long-term ecosystem development. Supporters are actively engaging in the projects community spaces and scavenger hunts, framing the asset as a culture-driven alternative to traditional market tokens.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing massive momentum and high volatility due to a favorable executive order from the Trump administration that aims to fast-track research and federal funding for ibogaine treatments. The community is actively discussing a potential short squeeze, citing the stock's exceptionally low float, while debates persist between bulls betting on triple-digit gains and bears warning of a potential pump-and-dump scenario.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as a major beneficiary of the AI infrastructure super-cycle, driven by a surge in demand for optical interconnects and custom silicon. The community is actively discussing its potential for continued growth, buoyed by strategic partnerships and analyst sentiment positioning it as a core player in next-generation AI hardware.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant traction as a top-tier quantum play, with investors increasingly focused on its strategic partnerships with NVIDIA and its growing portfolio of government and aerospace contracts. Community sentiment is largely bullish, with many focusing on the stock's potential for a short squeeze and its perceived undervaluation relative to other players in the quantum sector.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in SOXS are expressing intense frustration as the fund continues to slide despite ongoing geopolitical tensions and volatility in the semiconductor sector. The community is heavily focused on the rapid ascent of the underlying index, with many debating whether the current market momentum is a sustainable rally or a bubble-like blow-off top that will eventually trigger a sharp reversal.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing significant momentum driven by a Trump executive order that fast-tracks FDA pathways for psychedelic research, fueling speculation about potential National Priority Vouchers. Investors are closely watching for Phase 3 clinical data readouts in 2026 and debating the impact of the company's rebranding, historical cash burn, and future acquisition prospects.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is gaining momentum as investors pivot toward AI infrastructure, with the community actively monitoring its potential as a high-capacity data center provider following sector-wide growth. Traders are closely tracking bullish options flow and structural breakouts, focusing on whether the company's energy capacity and leasing strategy can drive a move toward previous highs.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as the market reacts to the White House executive order aimed at accelerating FDA review and research funding for psychedelic treatments, with many in the community viewing the directive as a major regulatory catalyst for the sector. Investors are actively discussing the company's status as a leader with completed Phase 3 trials, while debating potential risks like share dilution and the ongoing competitive landscape for mental health therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Plus has appointed Eric J. Daniels as its chief development officer, effective April 20.</li><li>The company also received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.</li></ul>Shares of Plus Therapeutics Inc. (PSTV) rallied 24% on Friday on the heels of the company announcing the appointment of a new chief development officer (CDO) and the U.S. Food and Drug Administration granting its experimental therapy an orphan drug designation.The stock is on track to record its best week since late September if the gains hold.Plus Therapeutics announced a 1-for-25 stock split last month in a bid to meet Nasdaq’s requirements for minimum share price for continued trading on the bourse. The stock began trading on a post-split basis on April 2.Houston, Texas-headquartered Plus has since announced that it has appointed Eric J. Daniels as its CDO, effective April 20. Daniels most recently was CDO at Kiora Pharmaceuticals, overseeing the company’s clinical, preclinical, and Chemistry, Manufacturing, and Controls (CMC) activities, Plus said.The company also said earlier this week that the FDA has granted Orphan Drug Designation to its radiotherapeutic REYOBIQ for the treatment of pediatric malignant gliomas, or aggressive brain tumors.Orphan Drug Designation is granted by the FDA to investigational therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation provides several potential benefits including tax credits, fee waivers, and potential market exclusivity.The company also said that it received FDA‘s green light to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PSTV stock stayed within the ‘extremely bullish’ territory over the past 12 months, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed pessimism about the company’s new CDO appointment, noting that Kiora shares slumped over the past year.<stembedurl>https://www.stocktwits.com/andre82/message/649952051</stembedurl>Yet another, however, said that the stock is very undervalued.<stembedurl>https://www.stocktwits.com/RadioIsotope25/message/649951802</stembedurl><a href="https://stocktwits.com/symbol/PSTV">PSTV stock</a> has dropped about 76% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-dives-after-fda-refuses-approval-for-skin-cancer-drug/cZJ0Kb3RIto">REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PSTV Stock On Track For Best Week Since September — Here’s What Is Driving The Rally

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 

Equity

Earlier this week, Plus Therapeutics said that the FDA has granted Orphan Drug Designation to its experimental drug REYOBIQ for the treatment of pediatric malignant gliomas. 


Why Is Plus Therapeutics Stock Gaining Friday?

Plus Therapeutics stock jumps after FDA grants Orphan Drug status to Reyobiq for pediatric brain cancer, boosting long-term outlook.read more...

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's Why

Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9% - Here's What Happened...

Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4

Plus (PSTV) delivered earnings and revenue surprises of +100.00% and +2.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +35.47% and +128.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Guardian Pharmacy Services (GRDN) Surpasses Q4 Earnings and Revenue Estimates

Guardian Pharmacy (GRDN) delivered earnings and revenue surprises of +37.04% and +2.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of +6.01% and +38.05%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Plus Therapeutics, Inc. (NASDAQ:PSTV) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the company...

Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven brokerages that are presently covering the company...

Plus Therapeutics (NASDAQ:PSTV) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $5.00 price target on shares of Plus Therapeutics in a research report on Thursday...

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

PSTV
Plus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PSTV News

PSTVPlus Therapeutics Inc